Valeant Pharma (VRX) Reports Q2 Loss of $0.11, Adj-EBITDA Beats; Maintains FY EPS, Lowers FY Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Announces Second-Quarter 2017 Results
August 8, 2017 7:00 AM EDTLAVAL, Quebec, Aug. 8, 2017 /PRNewswire/ --
Second-Quarter 2017 Financial Results Revenues of $2.233 Billion GAAP Net Loss of $38 Million Adjusted Net Income (non-GAAP) of $362 Million Year-to-Date GAAP Cash Flow from Operations of $1.222 Billion Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 Million Delivered Strong Organic Growth1Â (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Expects to Exceed $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue Guidance Range and Maintains 2017 Full-Year Adjusted EBITDA (non-GAAP)... More